Health Plan Design Challenges and the Impact of HSAs on Healthcare Use
Paul Fronstin, director of Health Benefits Research at EBRI, spoke with MHE about the challenges employers face in incentivizing high-value healthcare while managing costs.
Managed Healthcare Executive editors connected with Paul Fronstin, director of Health Benefits Research at EBRI, to discuss trends in health plan benefit design and the role of high-deductible health plans and HSAs.
Fronstin addressed that employers face challenges in incentivizing high-value healthcare while managing costs.
For example, the IRS's 2019 decision to allow certain preventive services such as insulin to be covered before deductibles saw 75% of employers quickly adopting at least one of these services.
Fronstin noted that "employers would like to figure out a way to incentivize the use of high-value providers...but haven’t quite gotten it right yet.”
On HSAs, he compared the difference between their impact and that of deductibles, highlighting that higher deductibles initially reduce healthcare utilization, but over time are stable.
In addition, Fronstin talked about HSAs as savings compared to spending accounts.
Despite their potential for long-term savings, many people use them to cover current healthcare costs.
He added that recent studies have shown a slight increase in medication adherence when certain drugs were removed from deductibles, supporting the importance of accessible preventive care.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Opzelura May Reduce Need for Other Treatments in Atopic Dermatitis | AAD 2025
March 11th 2025Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics during the 12 months after treatment with the topical nonsteroidal, finds study at American Academy of Dermatology Association annual meeting.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Supporting Patients with Type 1 Diabetes Through Education, Technology and Transparency
March 10th 2025Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.
Read More
Melanoma Treatment Advances Now Crossing into Other Skin Cancers
March 10th 2025Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with advanced basal cell carcinoma, squamous cell carcinoma and Merkel cell carcinoma, which is a rare and aggressive type of skin cancer.
Read More
